Source link : https://newshealth.biz/health-news/blockbuster-drug-lands-first-line-indication-for-her2-positive-breast-cancer/
(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. Approval was based on results… Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/119027 Author : Publish date : 2025-12-15 21:28:00 Copyright for syndicated content belongs to the linked Source.
The post Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-15 21:28:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8